© PR Newswire
11.12.2025
950
LISTED
HKSE
Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
News Preview
Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potentialSynergistic and complementary to Lee's Pharm's existing products pipeline, andAcquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCBHONG KONG, Dec. 11, 2025 /PRNewswire/ -- Nova ...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.12.2025
AIML
LISTED
CSE
AIML Announces Engagement of Guerilla Capital for Communications and Investor Outreach Efforts
News Preview
TORONTO, ON / ACCESS Newswire / December 11, 2025 / AI/ML Innovations Inc. (CSE:AIML) ("AIML" or the "Company") is pleased to announce the engagement of Guerilla Capital ("Guerilla"), an arm's length investor relations firm with offices in Ontario, Canada. Guerilla will provide investor relations services to the Compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D
News Preview
STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy SVF-001, targeting hepatitis B and D, as a late-breaking abstract at the HepDart scientific meeting held December 7-11 in Honolulu, Hawaii. The results are...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
11.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
News Preview
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interva...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
11.12.2025
BIOV
LISTED
XWSX
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
News Preview
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. December 11, 2025, 7am CEST
BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027
Significant value inflection poi......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
1SXP
LISTED
XETR
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
News Preview
SCHOTT Pharma erreicht Jahresziele für Umsatz und Profitabilität
Währungsbereinigtes Umsatzwachstum von 5,8 % auf 986,2 Mio. EUR
Währungsbereinigte EBITDA-Marge steigt auf 28,4 % (Vorjahr: 26,9 %)
Anteil margenstarker High Value Solutions (HVS) bei 57 % (Vorjahr: 55 %)
Prognose für 2026: Währungsbereinigtes Umsatzwachstum von 2–5 % und EBITDA-M......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
AFX
LISTED
XETR
Carl Zeiss Meditec schließt das Geschäftsjahr 2024/25 mit solidem Umsatzwachstum und einem leichten Anstieg des EBITA ab
News Preview
Carl Zeiss Meditec schließt das Geschäftsjahr 2024/25 mit solidem Umsatzwachstum und einem leichten Anstieg des EBITA[1] ab
Umsatzwachstum bei Geräten und Verbrauchsmaterialien sowie stärkere Auftragseingänge und Auftragsbestände zum Jahresende
JENA, 11. Dezember 2025
Carl Zeiss Meditec erreichte im Geschäftsjahr 2024/25 einen Umsatz v......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
1SXP
LISTED
XETR
SCHOTT Pharma delivers on full-year revenue and profitability targets
News Preview
SCHOTT Pharma delivers on full-year revenue and profitability targets
Revenue of EUR 986.2m reflects a 5.8% growth at constant currencies
EBITDA margin at constant currencies increased to 28.4% (prior year: 26.9%)
Successful expansion of high-value solutions (HVS) – revenue share increased to 57% (prior year: 55%)
Guidance for FY 2026: 2-5% rev......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2025
AFX
LISTED
XETR
Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA
News Preview
Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA[1]
Growth in both equipment and consumables sales, along with stronger order intake and higher order backlogs at year-end
JENA, 11 December 2025
Carl Zeiss Meditec achieved revenue of EUR 2,228 million in fiscal year 2024/25 (prior year:......
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
GMAB
LISTED
CPH
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
IPH
LISTED
EURONEXT
Innate Pharma Releases Its 2026 Financial Calendar
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar:
March 26, 2026: Publication of 2025 financial statements
May 13, 2026: Publication of revenue and cash position for 1Q2026
May 21, 2026: Annual General Shareholders Meeting
September 17, 2026: Publi...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
GALD
LISTED
XWSX
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrol...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
11.12.2025
ZOM
LISTED
XASE
Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
News Preview
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated movie Merv now available on Prime Video ANN ARBOR, MI / ACCESS Newswire / December 11, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
IMVT
LISTED
NASDAQ
Immunovant Announces Pricing of $550 Million Common Stock Financing
News Preview
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before de...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
BSLN
LISTED
SIX
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
News Preview
Allschwil, Switzerland, December 11, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ZEAL
LISTED
CPH
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
News Preview
Press release – No. 19 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ZEAL
LISTED
CPH
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
News Preview
Press release – No. 18 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
SAN
LISTED
EURONEXT
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
News Preview
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
IBAB
LISTED
EURONEXT
China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology to expand its production capacity
News Preview
Louvain-la-Neuve, Belgium, December 11, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with China Gold Irradiation (CGI), the largest high standard irradiation service company in...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ROG
LISTED
SIX
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
News Preview
Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establishes Roche's in-vitro diagnostics (IVD) menu as the broadest available for any automated mass spectrometry platform, including already 39 of the most fr...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
ADXN
LISTED
SIX
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
News Preview
Ad Hoc Announcement Pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
9926
LISTED
HKSE
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
News Preview
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic tri...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.12.2025
GENF
LISTED
LSE
Genflow to Attend Healthcare Conference
News Preview
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healt...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
News Preview
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
NTRA
LISTED
NASDAQ
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study.
Presented today at the San Ant...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2025
LABS
LISTED
TSX
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
News Preview
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2025
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,820 shares of common stock and 7,840 restricted stock units (“RSUs”) to eight new employees under Mirum’s 2020 Inducement P...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
207940
LISTED
KOE
Samsung Biologics recognized as a global leader in water security
News Preview
Company receives the highest Water Security rating in two years into participationRecognized for exceptional leadership in environmental stewardshipINCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from t...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
45030
LISTED
XJPX
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
News Preview
- Data reflect new insights and precision oncology advancements in portfolio and pipeline -- Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking oral presentation -TOKYO, Dec. 10, 2025 /PRNewswire/ -- Aste...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2025
6492
LISTED
TAI
Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors
News Preview
TAIPEI and SAN DIEGO, Dec. 10, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a clinical supply agreement with BeOne Medicines, a global oncology company. This agreement will supply a global, multi-center Phas...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
INFU
LISTED
XASE
Ambulatory Infusion Pumps used in Pain Management Business by InfuSystem to Receive Separate Payment Under NOPAIN Act Starting January 1, 2026
News Preview
InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that the Centers for Medicare and Medicaid Services (“CMS”) has added two of the electronic infusion pu...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
FTRE
LISTED
NASDAQ
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
News Preview
DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on December 10, 2025, to two newly hired employees. The award consisted of 245,000 RSUs that vest in three equal annual inst...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
CTOR
LISTED
NASDAQ
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
News Preview
CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor, pric...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2025
DTC
LISTED
CSE
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
News Preview
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announ...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
NDSN
LISTED
NASDAQ
Nordson Corporation Reports Record Fourth Quarter and Fiscal Year 2025 Results
News Preview
Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal fourth quarter ended October 31, 2025. Sales were $752 million, a 1% increase compared to the prior year’s fourth quarter sales of $744 million. The increase in fourth quarter 2025 sales included favorable currency translation of 2% and a 1% acquisition impact, which was part...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
ANTM
LISTED
NYSE
Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence
News Preview
The board of directors of Elevance Health (NYSE: ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
BMY
LISTED
NYSE
Bristol Myers Squibb Announces Dividend Increase
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026.
This quarterly dividend repres...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
CERS
LISTED
NASDAQ
Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America
News Preview
Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus’ entire INTERCEPT product line....
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
CYH
LISTED
NYSE
Community Health Systems Appoints Kevin Hammons Chief Executive Officer and Jason Johnson Chief Financial Officer
News Preview
Community Health Systems, Inc. (NYSE: CYH) (the “Company” or “CHS”) announced today that the Company’s Board of Directors has appointed Kevin Hammons to chief executive officer and Jason Johnson to chief financial officer, effective immediately. Hammons and Johnson have been serving in these roles on an interim basis since October 1, 2025. Hammons...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2025
CRTX
LISTED
NASDAQ
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
LBRX
LISTED
NASDAQ
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
KEQU
LISTED
NASDAQ
Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026
News Preview
STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2025.
Fiscal Year 2026 Second Quarter Results:Sales during the second qua...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
NUVL
LISTED
NASDAQ
Nuvalent Appoints Ron Squarer to Board of Directors
News Preview
CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
CRNX
LISTED
NASDAQ
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 39,575 shares of its common stock and granted an aggregate of 26,525 restricted stock uni...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
IMAB
LISTED
NASDAQ
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
News Preview
ROCKVILLE, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced the presentation of new data from the expanded 3mg/kg every 6 week (Q6W) Phase 1 dosing study for ragistomig, a bispeci...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
AGE
LISTED
XASE
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
News Preview
– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
BBOT
LISTED
NASDAQ
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced late-breaking preclinical data on BBO-10203, a first-in-class covalent small molecule RAS:PI3Kα breaker that selectively and s...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
AARD
LISTED
NASDAQ
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
News Preview
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
News Preview
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
RYTM
LISTED
NASDAQ
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
News Preview
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
TLX
LISTED
ASX
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
News Preview
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic prod...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
MAIA
LISTED
XASE
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
News Preview
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class—telomere-targeting agents—i...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
AZTA
LISTED
NASDAQ
Azenta Authorizes $250 Million Share Repurchase Program
News Preview
BURLINGTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock. The Repurchase Program is intended to enhance shareholder value and capitalize on undervaluation....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.12.2025
SKNY
LISTED
CSE
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
News Preview
VANCOUVER, BC / ACCESS Newswire / December 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative cell-penetrating peptide-based uptake study (the "Study") of GLP/GIP[1]-based obesity therapies, further advancing its nov...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2025
HEM
LISTED
TSX
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
News Preview
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure,...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
EL
LISTED
EURONEXT
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear
News Preview
EssilorLuxottica joins forces with Fondazione Chips-ITto accelerate the future of smart eyewear...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
GNFT
LISTED
EURONEXT
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today reports encouraging preliminary Phase 1b data from its CCA clinical trial evaluating GNS561 in comb...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
EQS
LISTED
EURONEXT
EQUASENS ANNOUNCES ITS 2026 FINANCIAL CALENDAR
News Preview
Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year....
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2025
INNO
LISTED
CSE
Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering
News Preview
HERZLIYA, Israel and CALGARY, AB, Dec. 10, 2025 /PRNewswire/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that, further to its press release of July 23, 2025, it has publicly filed an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
EAPI
LISTED
EURONEXT
Tristan Imbert co-opted as Independent Director
News Preview
Paris – December 10, 2025 - EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to t...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
